Amylyx Pharmaceuticals is a clinical stage biotechnology company. Co. is developing therapies for amyotrophic lateral sclerosis (ALS) and a range of other neurodegenerative diseases, including Alzheimer's Disease, Wolfram syndrome, Parkinson's Disease, Huntington's Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, primary lateral sclerosis, ischemic stroke, multiple sclerosis, Friedreich's ataxia, and Leigh's syndrome. Co. is pursuing commercialization of AMX0035, which is a drug candidate for patients with ALS. AMX0035 is a dual unfolded protein response-Bcl-2 Associated X-protein apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid. We show 6 historical shares outstanding datapoints in our AMLX shares outstanding history coverage, used to compute AMLX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AMLX market cap history over the course of time is important for investors
interested in comparing AMLX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AMLX versus a peer is one thing; comparing
AMLX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AMLX can fluctuate over the course of history.
With this page we aim to empower investors researching AMLX by allowing them to research the AMLX market cap history. |
Free AMLX Email Alerts:
Video: The Importance of Market Cap
